BRAIN Biotech AG

BNN

Equity

ISIN DE0005203947 / Valor 30933824

Xetra (2024-09-18)

EUR 1.45-0.34%

BRAIN Biotech AG
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

BRAIN Biotech AG is a leading biotechnology company that offers top-notch research and development services, specialized production expertise, and access to lucrative markets. The company operates as a group of self-sufficient entities that collaborate to synergize in research and development, particularly in the fields of biotechnology and natural product chemistry. One of its key units, Bioprocess Development, functions as a Contract Research Organization (CRO) that focuses on developing, optimizing, and scaling up microbial production processes for clients. The company's team of experts utilizes a wide range of technical and support skills to successfully implement these processes for their customers.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

In the second quarter of the 2023/24 financial year, BRAIN Biotech AG reported a revenue increase of €1.0 million, or 7.4%, reaching €14.5 million. This growth was significantly bolstered by a large milestone payment for the successful progress of the deucrictibant project, recognized in the BioIncubator segment.

Operating Performance

Despite the revenue growth, BRAIN Biotech AG's total operating performance for the first six months of 2023/24 decreased by 2.6%, from €28.1 million to €27.4 million. This decline was primarily due to negative changes in inventories and lower other income compared to the same period of the previous year.

Cost Management

The cost of materials for BRAIN Biotech AG decreased from €13.0 million to €11.2 million year-on-year. However, personnel expenses increased by 6.2%, from €11.4 million to €12.1 million, driven primarily by higher wages and salaries. Other expenses remained roughly the same as the previous year, at €5.0 million.

Segment Performance

In the BioProducts segment, revenues decreased by 5.0% from €20.9 million to €19.8 million. Conversely, the BioIncubator segment saw a significant revenue increase from €0.2 million to €1.6 million, largely due to a milestone achievement in the deucrictibant project. The BioScience segment experienced a slight revenue decline of 5.3%, from €6.1 million to €5.8 million.

Cash Flow and Financial Position

BRAIN Biotech AG's cash flow from operating activities improved from €-5.6 million to €-3.2 million in the first half of the 2023/24 financial year. This improvement was mainly due to a reduction in inventories and the collection of trade receivables. Overall, cash and cash equivalents increased from €5.4 million to €10.2 million compared to 30 September 2023.

Summarized from source with an LLMView Source

Key figures

-68.1%1Y

-85.2%3Y

-85.8%5Y

Performance

54.4%1Y

49.6%3Y

50.2%5Y

Volatility